After years of steady increase, opioid overdose deaths in the United States dropped sharply in 2023 — and continued falling into 2024. A new analysis suggests that the reversal may not be driven by better policy or treatment access, but by something more fragile: a disruption in the illicit fentanyl supply.
For South Dakota, where overdoses touch families from Sioux Falls to reservation communities to small towns with limited treatment access, the finding raises a hard question: what happens when the supply comes back?
WHAT CHANGED — NATIONALLY
According to the analysis summarized in JAMA, researchers found multiple indicators pointing to a fentanyl “drought” beginning in mid-2023. Drug purity declined, fentanyl seizures reported by law enforcement fell, and online drug-user forums showed increased discussion of shortages — all coinciding with a drop in overdose deaths.
The disruption may be linked to actions by the Chinese government to restrict production and export of fentanyl precursor chemicals, a key upstream factor in the illicit drug market.
Researchers cautioned that supply-side shocks are often temporary. But they argued the decline presents a rare opening to expand prevention and treatment programs that reduce demand — before availability rebounds.
WHY THIS MATTERS IN SOUTH DAKOTA
South Dakota has long faced a quieter version of the opioid crisis: fewer people overall than coastal states, but steeper consequences for those affected. Limited treatment capacity, long travel distances, housing instability, and shortages of behavioral-health providers mean overdoses often unfold far from help.
When fentanyl potency fluctuates, people who use drugs face the highest risk. A sudden return to higher purity can be deadly — especially for people whose tolerance dropped during a supply disruption.
For families, the impact is immediate and personal: parents who don’t come home, children entering foster care, workers lost from already-thin labor pools, and emergency responders stretched by repeat crises.
GOVERNANCE CHOICES — NOT JUST PUBLIC HEALTH
The JAMA analysis underscores a governance problem as much as a medical one. If overdose deaths fell primarily because fentanyl was harder to get, the improvement rests on forces South Dakota does not control.
State leaders still control whether this moment is used to expand access to medication-assisted treatment, strengthen overdose-reversal distribution, stabilize housing and mental-health supports, and reduce gaps in rural and tribal care.
Or whether the state simply rides the downturn — and absorbs the next surge when supply normalizes.
ACCOUNTABILITY LINE
We’ll be watching whether lawmakers follow through on expanding treatment and overdose-prevention funding when final budget decisions are made later this session.
THE BOTTOM LINE
A disrupted fentanyl supply may be buying time. It is not solving the problem.
For South Dakota, the difference between a temporary dip and a lasting decline in overdose deaths will come down to whether policymakers treat this moment as a warning — or a false sense of relief.
